Astoria Strategic Wealth, Inc. has recently announced that it has increased stake in Heart Test Laboratories Inc (NASDAQ:HSCS) by 246.09%. After grabbing 81995.0 shares, the institutional investor is now in possession of 58303.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.17% having worth around $19843.0. Moreover, Geode Capital Management LLC increased its share by 42316.0 to have a control over 42316.0 shares. And Citadel Securities LLC raised its holdings to 30586.0 shares by acquiring 30586.0 shares or 0.06% of the stake.
Heart Test Laboratories Inc (HSCS) concluded trading on 12/21/23 at a closing price of $0.16, with 2.69 million shares of worth about $0.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.47% during that period and on Thursday the price saw a loss of about -1.50%. Currently the company’s common shares owned by public are about 10.12M shares, out of which, 8.77M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company recently came buying 0.0 shares which brought its stake up to 0.09% of the company’s outstanding shares. Vanguard Extended Market Index Fu sold 100.0 shares, after which its hold over company’s outstanding shares shrunk to 0.00%, leaving 0.0 shares with the mutual fund that have a worth of about $0.0.
However, the stock later moved at a day high price of 0.1630, or with a loss of -1.50%. Stock saw a price change of -0.13% in past 5 days and over the past one month there was a price change of -19.53%. Year-to-date (YTD), HSCS shares are showing a performance of -81.21% which decreased to -80.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.14 but also hit the highest price of $3.95 during that period. The average intraday trading volume for Heart Test Laboratories Inc shares is 8.26 million. The stock is currently trading -18.96% below its 20-day simple moving average (SMA20), while that difference is down -32.16% for SMA50 and it goes to -77.97% lower than SMA200.
Astoria Strategic Wealth, Inc. acquired 81995.0 shares of Heart Test Laboratories Inc having value of about $19843.0. Data submitted at the U.S SEC by Astoria Strategic Wealth, Inc. revealed that the firm now holds 58303.0 shares in the company valued at close to $9328.48, or have control over 246.09% stake in the company. Heart Test Laboratories Inc (NASDAQ: HSCS) currently have 10.12M outstanding shares and institutions hold larger chunk of about 4.85% of that. Holding of mutual funds in the company is about 1.03% while other institutional holders and individual stake holders have control over 2.43% and 0.09% of the stake respectively.
The stock has a current market capitalization of $1.77M and its 3Y-monthly beta is at 3.78. It has posted earnings per share of -$0.61 in the same period. It has Quick Ratio of 0.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HSCS, volatility over the week remained 8.77% while standing at 14.23% over the month.
Analysts are in expectations that Heart Test Laboratories Inc (HSCS) stock would likely to be making an EPS of -$0.13 in the current quarter, while forecast for next quarter EPS is -$0.13 and it is -$0.56 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.13 which is -$0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.16 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.25% while it is estimated to decrease by -9.80% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Heart Test Laboratories Inc (HSCS)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
